Ache-free Investment Opportunities in Neuropathic Pain

In the United States, up to 50 million people live with chronic pain, with the majority of these patients not satisfied with their current pain treatments.  Pain is defined clinically as an unpleasant emotional experience resulting from real or potential tissue damage and is generally divided into two categories based on cause:

Nociceptive pain, which is [...]

Novel Diabetes Therapies Presented at 2009 ADA Meeting

Approximately 250 million people worldwide have been diagnosed with diabetes mellitus and that number is growing with the increasing obesity population.  Broadly, patients with diabetes are characterized by elevated blood glucose levels that result from either insufficient insulin secretion (type-1 diabetes) or ineffective insulin action (type-2 diabetes).  The market for treating patients with diabetes is [...]

Keryx: Another beneficiary of the ASCO-effect

In my prior article, I highlighted the “ASCO-effect,” which relates to the fact that biotechnology companies working in the field of cancer can experience double or triple-digit stock price increases from the end of April through the American Society of Clinical Oncology (ASCO) annual meeting. Beyond the names previously mentioned, investors also appear to be [...]